Girish Mahajan (Editor)

Romosozumab

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Whole antibody

Target
  
Sclerostin

Legal status
  
Investigational

Source
  
Humanized (from mouse)

ATC code
  
none

CAS Number
  
909395-70-6

Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis.

Romosozumab was originally discovered by Celltech (now owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product's development.

References

Romosozumab Wikipedia